AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win
Positive Phase III For Ionis-Partnered Antisense Candidate
AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.
